Structured intelligence coverage

Structured records are temporarily unavailable. The published profile and its source ledger remain accessible.

Identity checks do not refresh the age of governance evidence. Open a record for its source date and review state.

Overview

Business, legal identity, ownership structure and classifications.

What the company does

About

ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers.

Sector and industry values retain their source labels. A classification provider, taxonomy version and assignment date are not established unless the cited record states them.

Stable business record

Identity and status

Ownership and listing state

Public listing published

Ownership not asserted

The canonical public record includes at least one active security listing.

Inspect status source
Legal name
ArriVent BioPharma, Inc.
Inspect source
Country
US
Inspect source
Sector
Healthcare
Inspect source
Industry
Biotechnology
Inspect source

Source-backed public-market identity

Index memberships

Current memberships are attached to a specific security and listing. Announcements, effective dates, and removals remain distinct states; Alpha does not infer membership from company size, exchange, or reputation.

No current membership is published in Alpha's tracked index universe.

This is not evidence that the company is absent from every market index.

As of Sep 24, 2026. Rights-filtered public evidence only; no redistribution or model training is granted.

Only source-backed memberships with an explicit public redistribution basis are returned.

Relationships and related records

Connections

Explore the roles, education and affiliations published in this record.

Carl L. Gordon, Ph.D., CFA

Open Carl L. Gordon, Ph.D., CFA profile →
Carl L. Gordon, Ph…Carl L. Gordon, Ph.D., CFAChris W. NoletChris W. NoletJames Healy, M.D.,…James Healy, M.D., Ph.D.John Hohneker, M.D.John Hohneker, M.D.Kristine PetersonKristine PetersonMerdad Parsey, M.D…Merdad Parsey, M.D., Ph.D.Stuart Lutzker, M.…Stuart Lutzker, M.D., Ph.D.Zarath Summers, Ph…Zarath Summers, Ph.D.ArriVent BioPharma…

Dashed lines mark past roles. Select a connection to see its dates and sources.

Published record

Featured coverage

Selected publications and public sources used to establish this profile. Inclusion records provenance; it is not an endorsement.

Source 1 · canonical_identityAlpha canonical company public projectionSupports Company identity, Published leadership, Entity status boundary. Reviewed Sep 24, 2026.Open source

Board & Leadership

Board leadership, management, committees and their disclosed responsibilities.

Committee appointments · Temporarily unavailable

Structured records for this section are unavailable. This does not establish that no records exist. Published profile sources remain in Evidence & History.

Canonical AEGIS identity graph

Executive leadership

Current, confirmed roles are shown only when both the person Profile and supporting source record satisfy the public projection boundary. A missing role is not evidence that it does not exist.

Executive team

0 public records

Executive roster coverage is NOT_ASSERTED. An empty list is not evidence that this company has no executive team.

Governance leadership

Boards & Committees

Board and committee assignments appear only when the canonical public projection retains a current role and supporting source. Unpublished records are not interpreted as absence.

Record as of Sep 24, 2026. Chair, executive office, Lead Independent Director and committee appointments retain their separate source roles. A complete board composition denominator and committee charters are not established by a partial roster.

Board roles

8 public records

Disclosure boundary

Governance and independence

Only current, confirmed leadership roles with public evidence are included in the canonical projection.

RecordStatusAuthorityEffective

Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.

Financials & Filings

Reported statements, original filings and proxy disclosures with their reporting periods.

Financial statements · Temporarily unavailable

Structured records for this section are unavailable. This does not establish that no records exist. Published profile sources remain in Evidence & History.

Filing library · Temporarily unavailable

Structured records for this section are unavailable. This does not establish that no records exist. Published profile sources remain in Evidence & History.

Proxy & Voting · Temporarily unavailable

Structured records for this section are unavailable. This does not establish that no records exist. Published profile sources remain in Evidence & History.

Ownership & Markets

Ownership, funding and dated financial information.

Ownership, control and market context · Temporarily unavailable

Structured records for this section are unavailable. This does not establish that no records exist. Published profile sources remain in Evidence & History.

Ownership disclosures retain their reporting dates and source types. Economic ownership, investment discretion and voting authority are distinct. Activism and settlement-dated short interest are not established by holdings or short-sale volume.

Risk & Assurance

Disclosed coverage, ratings and assurance scope.

Disclosures and oversight · Temporarily unavailable

Structured records for this section are unavailable. This does not establish that no records exist. Published profile sources remain in Evidence & History.

Credit-rating evidence, where published, appears in the Governance and Basis sections with its source and reporting date. Insurance coverage, cyber ratings and assurance reports require their own issuer, scope, date and usage rights. Indemnification does not establish insurance coverage.

Evidence & History

Identifiers, sources and record limitations.

Identifiers

Alpha ID
alpha:company:82ea3aa3-59aa-4f9c-b2fe-30b5fd54281c
Record version
public-1

Sources

Sources and published information

Published evidence records

2 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. Alpha canonical company public projection

    canonical identity · Source published: Date unavailable · Retrieved: Sep 24, 2026

    Supports 5 claims
    • Legal Name: ArriVent BioPharma, Inc. · Claim reviewed: Sep 24, 2026
    • Entity Status: Public listing published · Claim reviewed: Sep 24, 2026
    • Published Fact: US · Claim reviewed: Sep 24, 2026
    • Published Fact: Healthcare · Claim reviewed: Sep 24, 2026
    • Published Fact: Biotechnology · Claim reviewed: Sep 24, 2026

  2. ArriVent BioPharma, Inc. DEF 14A 2025-04-28

    sec proxy · Source published: Apr 28, 2025 · Retrieved: Apr 24, 2026

    Supports 8 claims
    • Leadership Role: Carl L. Gordon, Ph.D., CFA: Director · Claim reviewed: Sep 24, 2026
    • Leadership Role: Chris W. Nolet: Director · Claim reviewed: Sep 24, 2026
    • Leadership Role: James Healy, M.D., Ph.D.: Director · Claim reviewed: Sep 24, 2026
    • Leadership Role: John Hohneker, M.D.: Director · Claim reviewed: Sep 24, 2026
    • Leadership Role: Kristine Peterson: Director · Claim reviewed: Sep 24, 2026
    • Leadership Role: Merdad Parsey, M.D., Ph.D.: Director · Claim reviewed: Sep 24, 2026
    • Leadership Role: Stuart Lutzker, M.D., Ph.D.: Director · Claim reviewed: Sep 24, 2026
    • Leadership Role: Zarath Summers, Ph.D.: Director · Claim reviewed: Sep 24, 2026